The Burlingame Center for Psychiatric Research and Education

Mission: To promote excellence in clinical care through research and education.
	Learn More... Current Staff Clinical Information Management  Professional Education Current Research Studies Selected Publications & Presentations

The Clinical Evaluation and Monitoring System (CEMS)
The Burlingame Center operates the hospital's computerized clinical decision support system CEMS.  This automated decision support system, developed by John W. Goethe, M.D. and Bonnie L. Szarek, R.N., supports the goal of assuring the optimal outcome for every patient. The components of the system are:

• Psychotropic Guidelines: This on-line document summarizes key information about the use of selected psychiatric medications (dosages, therapeutic serum levels, indications and side effects). It also presents "decision trees" to guide drug selection. (more)
• Information Alerts: These computer-generated messages notify clinicians of events that do not conform to practice guidelines and medication protocols. Clinicians may respond to these notices by changing the treatment plan/diagnosis/laboratory orders to comply with "usual practice" (defined in the Pharmacotherapy Guidelines) or by documenting the reason for alternative treatment, using a standard form to record the response. (The response is then automatically entered as a progress note in the patient’s medical record.)
• Diagnostic Checklists (DCLs): The DCLs provide an automated method for assuring documentation of the key symptoms and behavioral issues that support the assigned diagnosis and for noting the degree of change in each symptom/behavior at subsequent evaluations (e.g., at discharge). There is a separate checklist for each psychiatric diagnosis that reflects DSM criteria for that diagnosis.
• Outcome Assessment Program (OAP): Clinical staff interview every patient at admission and discharge, using a brief questionnaire to assess items related to functioning and productivity. The patient is contacted at one, six, and twelve months post-discharge to assess functional status and subsequent psychiatric treatment received.  Manager: Steve Woolley, M.P.H., D.Sc. Coordinator: Brenda Woznicki.

• An 8-week, Placebo-controlled, Double-blind, Randomized, Fixed-dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects with Schizophrenia - Andrew Winokur, M.D., Ph.D., Principal Investigator; Salma Malik, M.D., Co-Principal Investigator 
• A 26-week, Mulit-center, Open-label, Flexible-dose, Long-term Safety Trial of Asenapine in Adolescent Subjects with Schizophrenia - Andrew Winokur, M.D., Ph.D., Principal Investigator; Salma Malik, M.D., Co-Principal Investigator
• Assessment of a Suicide Screening Program to Improve Detection of Post-Discharge Suicide Risk - Stephen Woolley, M.P.H., D.Sc., Principal Investigator
• Evaluation of Low Emission NeoSync EEG Synchronized Transcranial Magnetic Stimulation (sTMS) Technology for the Treatment of Major Depressive Disorder:  A Multicenter Randomized, Double-Blind, Sham-Controlled Trial - John W. Goethe, M.D., Principal Investigator
• Expectancy Therapy and Medication for Smoking Cessation - Adam Jaffe, Ph.D., Principal Investigator; Charles H. Wilber, M.Ed., Co-Investigator  
• A Phase III, Mulit-center, Randomized, 12-week Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients with Sub-optimally Controlled Symptoms of Schizophrenia Treated with Antipsychotics followed by a 40-week, Double-blind, Parellel-group, Placebo-controlled Treatment Period - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator  
• A Phase III, Mulit-center, Randomized, 24-week Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Stable Patients with Persistent, Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics followed by a 28-week, Double-blind Treatment Period - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
• A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study Comparing the Efficacy and Safety of Two Doses of LuAA21004 in Acute Treatment of Adults with Major Depressive Disorder - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
• Physiogenomic Analysis of Antipsychotic Therapies and their Metabolic Side Effects - Gualberto Ruaño, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
• Prevalence of Hyperhomocysteinemia in Patients with Schizophrenia Treated with Atypical Antipsychotics  - Charles Caley, Pharm.D., Principle Investigator
• Prospective Follow-up Study of the Effects of Locus-of-Control and Life Stressors on Long-Term Outcome of Treatment for Major Depressive Disorder - Stephen Woolley, M.P.H., D.Sc., Principal Investigator
• A Randomized, Double-blind, Parallel-group, Active- and Placebo-controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects with Treatment Resistant Major Depressive Disorder- Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
• SSRIs in the Treatment of Major Depressive Disorder: Side Effects and Patient Choices of Treatment - John W. Goethe, M.D., Principal Investigator; Steve Woolley, M.P.H., D.Sc., Co-Principal Investigator
• Extension of the Longitudinal Study of SSRIs in the Treatment of Major Depressive Disorder: Side Effects and Patient Choices of Treatment - Stephen Woolley, M.P.H., D.Sc., Principal Investigator
• The Utility of Routine Cytochrome P450 Genotyping in the Selection of Type and Dosage of Antidepressant Medication - John W. Goethe, M.D., Principal Investigator   

• Blair EW, Szarek BL, Azhar N.  Survey of osteoporosis in an inpatient geriatric psychiatric setting: a pilot study.  Issues in Mental Health Nursing, 31(6):403-407, 2010.
• Blair EW, Szarek BL.  Exploring relationship of psychotropic medication to fall events in an inpatient geriatric psychiatric population.  The International Journal of Psychiatric Nursing Research, 14(1), 2008.
• Blank K, Szarek BL, Goethe JW.  Metabolic abnormalities in adult and geriatric major depression with and without co-morbid dementia.  The Journal of Clinical Hypertension, 12(6):456-461, 2010.
• Blank K, Szarek BL, Goethe JW.  Metabolic abnormalities in patients with major depressive disorder.  Presented at the Annual Meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Blank K, Szarek BL, Goethe JW.  The influence of dementia on the treatment of depression in geriatric inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
• Bonetti J, Szarek BL, Goethe JW.  Current prescribing practices: antipsychotic polypharmacy in patients with schizophrenia and schizoaffective disorder.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
• Bullock K, Szarek BL, Goethe JW: Racial differences in major depressive disorder presentation. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.
• Bullock K, Goethe JW, Szarek BL.  Ethnic differences in length of stay and choice of antipsychotic medication among inpatients diagnosed with schizophrenia.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
• Bullock K, Szarek BL, Goethe JW.  Racial differences in prescribing practices in the treatment of patients diagnosed with schizophrenia.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
• Caley CF, Goethe JW, Woolley SB, Bardack D, Martello T, Azhar N.  Lifestyle, socioeconomics, and health history versus medications as predictors of metabolic syndrome.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
• Caley CF.  Psychiatric pharmacy in a university student health system.  Poster presentation at the 11th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Scottsdale, AZ, April 2008.
• Caley CF, Sopko M.  Chronic leukocystosis associated with clozapine treatment.   Poster presentation at the 11th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Scottsdale, AZ, April 2008.
• Caley CF.  Atypical antipsychotics in schizophrenia: evaluating adherence and relapse.  Presented at the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, The Broadmoor Hotel, Colorado Springs, Colorado, April 15, 2007.
• Caley CF. Treatment outcomes in schizophrenia: current issues and emerging options.  Symposium chair, 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado Springs, Colorado, April 2007.
• Caley CF.  More than the baby blues:  identification and management of postpartum depression.  Presented at the 155th Annual Meeting and Exposition of the American Pharmacy Association, Georgia Convention Center, Atlanta, Georgia, March 18, 2007.
• Caley CF.  Medication management for bipolar disorder:  advantages and disadvantages.  Presented at the Depression and Bipolar Support Alliance, Hartford, CT, December 2006.
• Caley CF.  Treatment resistant depression.  Presented at the 10th Annual Northeastern Psychiatric Pharmacotherapy Symposium, Northampton, Massachusetts, September 2006.
• Caley CF.  From San Diego to Baltimore.  Outgoing presidential address presented to members of the College of Psychiatric and Neurologic Pharmacists at the 9th Annual Meeting, Baltimore Waterfront Marriott Hotel, Baltimore, Maryland, April 25, 2006.
• Cardoni AA.  Opiod Dependence: From Cold Turkey to Acute Detox.  Psychopharmacology/Neuroscience Rounds, Institute of Living, Hartford, CT, February 16, 2011.
• Cardoni AA.  Opiod Dependence: Clinical Pharmacology and Treatment.  Presented at the Henry A. Palmer C.E. Finale 2010, Storrs, CT, December 17, 2010.
• Cardoni AA.  Management of Treatment-Resistant Depression - An Update.  Presented at the 33rd Annual Arthur E. Schwarting Pharmacy Practice Symposium, Storrs, CT, May 27, 2010. 
• Cardoni AA.  Tobacco culture and science in 2007: helping to clear the smoke for psychiatric staff and patients. Psychopharmacology/Neuroscience Rounds, Institute of Living, Hartford, CT, November 2007.
• Cardoni AA, Woolley SB, Goethe JW.  LOCF (Last Observation Carried Forward) and distortion of findings in a psychotropic drug clinical study.  Presented at the Annual Meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Cardoni AA, Woolley SB, Piez DA, Goethe JW.  Bupropion augmentation versus usual care in the treatment of patients with treatment-resistant depression.  Presented at the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, The Broadmoor Hotel, Colorado Springs, Colorado, April 17, 2007.
• Cardoni AA, Woolley SB, Piez DA, Goethe JW.  Bupropion augmentation versus usual care in the treatment of patients with treatment-resistant depression.  Poster presented at the Annual Meeting of the U.S. Psychiatric & Mental Health Congress, New Orleans, Louisiana, November 17, 2006.
• Cardoni AA.  Bipolar update.  Presented to the Department of Psychiatry, The Institute of Living, Hartford, Connecticut, September 2006.
• Cardoni AA, Woolley SB, Piez DA, Goethe JW.  Bupropion augmentation versus usual care in the treatment of patients with treatment-resistant depression.  Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
• Cardoni AA, Woolley SB, Piez DA, Goethe JW.  Treatment-resistant depression: changes in symptoms and functioning in a clinical sample.  Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
• Diefenbach GJ, Woolley SB, Goethe JW.  The association between self-reported anxiety symptoms and suicidality.  Journal of Nervous and Mental Disease, 197(2):92-97, 2009.
• Diefenbach GJ, Woolley SB, Goethe JW.  Anxiety symptoms among psychiatric outpatients: prevalence and association with suicide risk.  Poster presented at the Annual Meeting of the American Public Health Association, Washington, DC, November 2007.
• Diefenbach GJ, Goethe JW.  Clinical interventions for late-life anxious depression.  Clinical Interventions in Aging, 1:41-50, 2006.
• Ehret MJ, Szarek BL, Goethe JW.  Current prescribing practices: antidepressant use in schizophrenia. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
• Ehret MJ, Goethe JW, Szarek BL.  Who received guideline-based pharmacotherapy for bipolar depression?  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
• Ehret M, Shelton D, Wakai S, Zhang W.  Psychotropic medication adherence:  implications for post-release success.  Poster presentation at the 11th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Scottsdale, AZ, April 2008.
• Ehret MJ, Sopko MA, Levine A.  Iloperidone: a novel atypical antipsychotic for the treatment of schizophrenia.  Formulary, 43:190-203, 2008.
• Ehret MJ.  STAR-D: Where are we Now?  Presented at Northeastern Psychiatric Pharmacy Symposium, Northampton, MA, October 2007.
• Ehret MJ, Levin GM, Narasimhan M, Rathinavelu A.  Venlafaxine induces p-glycoprotein in human Caco-2 cells.  Hum Psychopharmacol Clin Exp, 22:49-53, 2007.
• Ehret MJ.  Pharmacogenomics of antidepressant medications.  Journal of Pharmacy Practice, 19:342-52, 2006.
• Ehret MJ, Chavez B.  A review of the STAR*D trial.  Journal of Pharmacy Practice, 19:353-60, 2006.
• Ehret MJ, Levin GM.  The long-term use of atypical antipsychotics in bipolar disorder.  Pharmacotherapy, 26(8):1134-47, 2006.
• Fogg-Waberski JH, Szarek BL, Knauft RF.  Electroconvulsive therapy for treatment of refractory depression in a patient with cystic fibrosis.  Journal of ECT,  22:72-3, 2006.
• Goethe JW.  Health care in crisis: readings for the new year.  Connecticut Medicine, 75:183-184, 2011.
• Goethe JW.  Healthcare research and the interface with psychodynamic understanding of behavior.  Presented at the Annual Meeting of the American Academy of Psychoanalysis and Dynamic Psychiatry, Honolulu, Hawaii, May 2011.
• Goethe JW, Szarek BL.  Diagnostic stability in major depressive disorder with versus without psychotic features.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
• Goethe JW, Szarek BL.  Inpatients with psychotic vs. nonpsychotic MDD: prevalence and clinical characteristics. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.  
• Goethe JW, Szarek BL.  Is schizoaffective disorder a distinct diagnostic entity?  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
• Goethe JW, Szarek BL, Caley CF.  Metabolic syndrome in psychiatric inpatients treated for depression.  In Thakore J, Leonard Be (eds), Metabolic Effects of Psychotropic Drugs, Modern Trends in Pharmacopsychiatry, Basel Karger, 26:90-104, 2009.
• Goethe JW, Szarek BL, Blank K, Caley CF.  Metabolic syndrome in patients with major depressive disorder: associated risk factors.  Psychiatric Times, January 1, 2009.
• Goethe JW.  Stuck in the black box: a patient safety approach to prescribing antidepressants.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
• Goethe JW, Woolley SB, Cardoni AA, Woznicki B, Piez DA.  Long-term follow-up of patients with major depressive disorder:  changes in symptoms, treatment and side effects.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
• Goethe JW, Szarek BL, Caley CF.  Metabolic syndrome and depression: a review.  Depression: Mind and Body, 3(4):138-149, 2008.
• Goethe JW, Szarek BL, Woolley SB, Caley CF.  Metabolic abnormalities in psychiatric inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Goethe JW.  Expanding the do no harm mandate.  Invited article.   Connecticut Medicine, 71:499-500, 2007.
• Goethe JW, Szarek BL, Caley CF, Woolley SB.  Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review.  J Clin Psychiatry, 68:22-8, 2007.
• Goethe JW, Woolley SB, Cardoni AA, Woznicki B, Piez DA.  Selective serotonin reuptake inhibitor discontinuation:  side effects and other factors that influence medication adherence.  J Clin Psychopharmacol, 27(5):451-8, 2007.
• Goethe JW, Woolley SB, Piez DA, Woznicki B.  Hopelessness and suicidality three months post-hospital discharge.  Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
• Goethe JW, Melman D.  Mind and brain: together again.  Invited article.  Connecticut Medicine, 70:599-600, 2006.
• Grgas M, Washburn Jr. CF, Caley CF. Clozapine-Induced Myocarditis: Two Case Reports. Poster to be presented at the 12th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Jacksonville, Florida, April 2009.
• Grgas M, Woolley SB, Ruaño G, Goethe JW, Szarek BL, Caley CF, Ehret MJ. An Analysis of CYP450 Genotype and Patients' Perceived Response and Tolerance to their Antidepressants. Poster to be presented at the 12th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Jacksonville, Florida, April 2009.
• Gugger JJ, Caley CF.  Clozapine treatment in a patient with a persistently low neutrophil count.  Poster presented at the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, The Broadmoor Hotel, Colorado Springs, Colorado, April 17, 2007.
• Gugger JJ, Caley CF, Goethe JW, Szarek BL, Ehret MJ, Woolley, SB.  The pharmacogenomics of antidepressant tolerance.  Poster presented at the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, The Broadmoor Hotel, Colorado Springs, Colorado, April 17, 2007.
• Gugger JJ, Caley CF.  Clozapine treatment in a patient with a persistently low neutrophil count.  Clinical Schizophrenia and Related Psychoses, 1:270–2, 2007.
• Levin GM, Bowles TA, Ehret MJ, et al.  Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness.  Mol Diag Ther, 11(3):155-60, 2007.
• Luque CA, Ehret MJ, Rey JA.  Rimonabant (Acomplia): the first cannabinoid-1 receptor blocker for obesity.  P&T, 32(4):209-213, 2007.
• Padole A, Woolley SB, Szarek BL, Goethe JW.  Variables Associated with 3-Month Incidence of Readmission: Patients with Schizophrenia versus Schizoaffective Disorder.  Poster presentation at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
• Popish SJ, Levin GM, Muthusamy K, Pandya N, Ehret MJ, Rathinavelu A.  Assessment of Ethnicity on the Butyrylcholinesterase Variant K Polymorphism.  Poster presented at the 11th Annual CPNP Meeting (Co-PI) Scottsdale, Arizona, April 2008.
• Ruaño G, Villagra D, Szarek BL, Windemuth A, Kocheria M, Berrezueta CD, Goethe JW.  Dyslipidemia in psychotropic-treated patients correlates with combinatorial CYP405 drug metabolism indices. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
• Ruaño G, Villagra D, Szarek BL, Windemuth A, Kocheria M, Goethe JW: Longer hospitalization associated with combinatorial CYP450 drug metabolism deficiencies. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010
• Ruaño G, Goethe JW, Windemuth A, Szarek BL.  Greater utilization of psychiatric services is associated with CYP450 drug metabolism deficiencies.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
• Ruaño G, Villagra D, Rahim US, Windemuth A, Kocheria M, Bower B, Szarek BL, Goethe JW.  Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital.  Personalized Medicine, 5:579-587, 2008.
• Ruaño G, Goethe JW, Windemuth A, Szarek BL.  Combinatorial cyp450 genotyping for depressed inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
• Ruaño G, Goethe JW, Windemuth A, Rahim US.  CYP genotyping in patients treated for depression.  Presented at the Annual Meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Ruaño G, Blair CL, Bower B, Windemuth A, Kocherla M, Aleman Y, Pearlson G, Goethe JW, Schwartz HI.  Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism deficiencies.  Connecticut Medicine, 71:197-200, 2007.
• Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocheria M, Windemuth de Leon AJ.  Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.  Mol Psychiatry, 12: 474-82, 2007.
• Ruaño G, Makowski G, Windemuth A, Kocherla M. Weiss S,  Goethe JW, Bower B, WU AHB, Thompson PD.  High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital:  Implications for personalized drug safety.  Personalized Medicine, 3:131-7, 2006.
• Ruaño GR, Zollner S, Goethe JW.  Drug induced metabolic syndrome (DIMS) in psychiatry:  A diagnostic need uniquely suited to pharmacogenomics.  In Wong SHY, Linder MW, Valdes R Jr. (Eds.) Pharmacogenomics and Proteomics:  Enabling the Practice of Personalized Medicine.  AACC Press, Washington, D.C., pp: 277-282, 2006.
• Shelton D, Ehret MJ.  Psychotropic Medication Adherence Patterns Among Adult Inmates.  Platform Presentation at the NCCHC Meeting, Correctional Mental Health: From Innovation to Practice, Las Vegas, Nevada, July 2008.
• Shelton D, Ehret MJ, Wakai S.  Psychotropic Medication Adherence: Implications for Post-Release Success.  Poster presented at the 11th Annual CPNP Meeting (Co-PI), Scottsdale, Arizona, April 2008.
• Shelton D, Ehret MJ, Wakai S.  Psychotropic Medication Adherence Among Adult Inmates.  Poster presented at the 20th Annual Scientific Conference Eastern Nursing Research Society, Philadelphia, PA, March 2008.
• Sopko MA, Ehret MJ, Woolley SB, Szarek BL, Goethe JW.  Rehospitalization rates among patients with schizophrenia.  Presented at the 11th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado Springs, CO, April 2008.
• Stevens MC, Szarek BL, Goethe JW.  Current prescribing practices: antipsychotic use in children and adolescents.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
• Stevens MC, Goethe JW, Francois DE, Szarek BL, Piez D.  Metabolic symptoms in adolescent inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
• Szarek BL, Goethe JW.  Patterns of antipsychotic use in hospitalized psychiatric patients.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011. 
• Szarek BL, Goethe JW.  Metabolic syndrome in psychiatric inpatients: The role of valproate and lithium.  Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.
• Szarek BL, Goethe JW, Woolley SB.  Assessing metabolic syndrome: waist circumference versus BMI.  Schizophrenia Research, 108(1-3):295-296, 2009.
• Szarek BL, Goethe JW. Diagnostic stability in patients with schizophrenia, schizoaffective and bipolar disorder.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
• Szarek BL, Goethe JW, Woolley SB.  Evidence-based medicine and outcome: three month follow-up of inpatients with MDD.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
• Szarek BL, Goethe JW, Woolley SB.  Indicators of treatment refractory illness and risk of suicide.  Presented at the Annual Meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Szarek BL, Goethe JW, Fogg-Waberski JH.  Predictors of referral for ECT.  Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
• Windemuth A, de Leon J, Goethe JW, Schwartz HI, Woolley SB, Susce M, Kocherla M, Bogaard K, Holford TR, Seip RL, Ruaño G.  Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.  Progress in Neuro-Psychopharmacology and Biological Psychiatry, 36(2):213-219, 2012.
• Woolley SB, Goethe JW, Szarek BL.  Risks of Readmission in Patients Diagnosed with Bipolar, Major Depressive, or Schizoaffective Disorders: a Longitudinal Study. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
• Woolley SB, Cardoni AA, Goethe JW.  An additional source of bias in antidepressant and other trials (authors' reply).  Pharmacotherapy, 30:117e-8e, 2010.
• Woolley SB, Goethe JW, Szarek BL, Tronsky M. The Association between pre-admission suicidality and readmission was modified by patient experiences, feelings and characteristics. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.  
• Woolley SB, Cardoni AA, Goethe JW.  Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies. Pharmacotherapy, 29:1408-16, 2009. 
• Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T.  Schizophrenia-Spectrum disorders were associated with cardiovascular disease symptoms, independent of known risk factors for symptoms.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
• Woolley SB, Fredman L, Goethe JW, Lincoln AK, Heeren T.  Headache complaints and the risk of suicidal thoughts or behaviors.  J Nerv Ment Dis, 196(11): 822-828, 2008.
• Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T.  Patients’ involvement in treatment decisions and antidepressant discontinuation.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
• Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T.  Severe headaches and the risk of subsequent suicidal thoughts or behaviors.  Presented at the Annual Meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Woolley SB, Goethe JW, May AM, Piez DA.  Distinguishing patients who attempt suicide from patients with ideation only.  Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
• Woolley SB, Pavel S, Goethe JW.  Locus-of-control and outcome of treatment for MDD.  Poster presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
• Woznicki BA, Woolley SB, Goethe JW, Bardack S, Azhar N.  Locus of control, life events, treatment history and longitudinal outcomes of treatment for depression.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.